News: Magenta Therapeutics appoints new Chief People Officer

Leadership

Magenta Therapeutics appoints new Chief People Officer

Stants is a seasoned human resources professional and she joins Magenta from Alexion Pharmaceuticals, where she served as Head of Talent Strategy, responsible for organizational development and talent acquisition to expand the company’s therapeutic pipeline.
Magenta Therapeutics appoints new Chief People Officer

Magenta Therapeutics a clinical-stage biotechnology company has announced the expansion of its senior leadership with two new strategic hires, Kristen Stants as Chief People Officer and Li Malmberg, Ph.D., as Senior Vice President, Head of Manufacturing.

“As Magenta continues to grow and make significant strides across our pipeline, our people and our manufacturing are more vital than ever to advance our vision to deliver curative immune reset to all patients who can benefit,” said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. “We welcome Kristen and Li’s invaluable leadership and deep expertise in building out these essential areas of focus for Magenta.”

Stants is a seasoned human resources professional and she joins Magenta from Alexion Pharmaceuticals, where she served as Head of Talent Strategy, responsible for organizational development and talent acquisition to expand the company’s therapeutic pipeline. 

Prior to that, she led talent management and development strategy at Patheon Pharmaceuticals, in addition to 10 years at Biogen, where she held various leadership roles in executive development and organizational effectiveness. Stants holds a Master of Industrial and Labor Relations with a concentration in Organizational Behavior from Cornell University and a Bachelor of Science in Psychology and Business from the University of Oregon.

Dr. Malmberg is an accomplished technical leader with more than 25 years of manufacturing experience, coming to Magenta from Celgene Corporation, where she served as Vice President, Head of Biologics Development and Manufacturing, responsible for the company’s manufacturing development and biologics manufacturing organization and advanced more than 20 biologics molecule and launched one commercial product.

Prior to this role, Dr. Malmberg was Director, Head of Process Sciences at Abbvie, Inc. where she built and led an organization of more than 80 scientists and engineers responsible for biologics drug development from preclinical to commercial launch. Previous roles include various leadership roles in R&D at Abbott Laboratories. She holds a Ph.D. in Chemical Engineering from the University of Minnesota-Twin Cities; a Master of Science in Chemical Engineering from the University of Wisconsin-Madison; and a Bachelor of Science in Chemical Engineering from the University of Illinois at Urbana-Champaign.

Read full story

Topics: Leadership, #Appointments

Did you find this story helpful?

Author

QUICK POLL

For how long do you think the current pandemic situation will impact the world of work?

How likely are you to recommend our content to a friend or colleague?

01
10
Selected Score :